Celldex Therapeutics, Inc. (CLDX) Receives $6.50 Average PT from Analysts
Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have earned a consensus rating of “Hold” from the ten ratings firms that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $6.50.
Several research analysts have recently weighed in on CLDX shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $9.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. HC Wainwright set a $10.00 price objective on Celldex Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research raised Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research report on Tuesday, July 11th. ValuEngine cut Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, BidaskClub cut Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th.
Celldex Therapeutics (NASDAQ CLDX) traded down $0.11 during mid-day trading on Thursday, hitting $2.38. The stock had a trading volume of 1,717,400 shares, compared to its average volume of 1,510,000. Celldex Therapeutics has a 52 week low of $2.20 and a 52 week high of $5.02.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.05. The company had revenue of $3.83 million during the quarter, compared to analysts’ expectations of $1.21 million. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. Celldex Therapeutics’s revenue for the quarter was up 175.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.32) earnings per share. research analysts anticipate that Celldex Therapeutics will post -1.03 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/11/07/celldex-therapeutics-inc-cldx-receives-6-50-average-pt-from-analysts.html.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Celldex Therapeutics by 7.8% during the second quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after acquiring an additional 708,095 shares in the last quarter. Meditor Group Ltd raised its holdings in Celldex Therapeutics by 8.8% during the third quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock worth $18,054,000 after acquiring an additional 512,700 shares in the last quarter. State Street Corp raised its holdings in Celldex Therapeutics by 4.7% during the first quarter. State Street Corp now owns 4,525,051 shares of the biopharmaceutical company’s stock worth $16,341,000 after acquiring an additional 202,375 shares in the last quarter. Northern Trust Corp raised its holdings in Celldex Therapeutics by 12.2% during the second quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after acquiring an additional 219,661 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Celldex Therapeutics by 42.4% during the first quarter. Renaissance Technologies LLC now owns 1,707,927 shares of the biopharmaceutical company’s stock worth $6,166,000 after acquiring an additional 508,217 shares in the last quarter. Institutional investors and hedge funds own 55.98% of the company’s stock.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.